Skip to main content
23724 search results for:

SCLC 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | SCLC | OriginalPaper

    Abnormal expression of LCA and CD43 in SCLC: a rare case report and brief literature review

    CD45 is a protein tyrosine phosphatase, also known as leukocyte common antigen (LCA), that is essential for the initiation of T-cell receptor signalling and is commonly used to diagnose lymphoid diseases [ 1 ].Although abnormal LCA expression has …

  2. Open Access 01-01-2025 | SCLC | ReviewPaper

    Predictive biomarkers for immunotherapy response in extensive-stage SCLC

    Among new cancer cases, lung cancer is the second most prevalent (11.4%) and the first most mortality (18%) worldwide, according to GLOBOCAN (Sung et al. 2021 ). According to the pathological types, lung cancer is divided into two subtypes: …

  3. Open Access 23-10-2023 | SCLC | ReviewPaper

    Novel therapeutic options for SCLC

    Small cell lung cancer (SCLC) accounts for about 10–20% of all lung cancers and it is characterized by a high rate of proliferation, early metastases

  4. 21-10-2023 | SCLC | News | Article
    ESMO 2023

    Tarlatamab shows promise for previously treated SCLC

    Tarlatamab has demonstrated durable antitumor activity and acceptable safety in previously treated patients with extensive-stage SCLC in the DeLLphi-301 trial.

  5. 15-09-2023 | BookReview

    SRS bei zerebraler Metastasierung beim SCLC?

    Das Überleben nach WBRT und SRS scheint gleich zu sein. Die Autoren äußern, dass zukünftige prospektive Studien den Stellenwert der WBRT und SRS in Abhängigkeit von der Tumorlast und der Lokalisation des Progresses klären sollten.

  6. Open Access 01-12-2023 | SCLC | OriginalPaper

    PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors

    Small cell lung cancer (SCLC) is an aggressive and relatively rare subtype of lung cancer, accounts for 13-15% of all lung cancer patients [ 1 , 2 ]. However, due to its hidden onset and insufficient early screening, about 70% of SCLC patients were …

  7. Open Access 07-07-2023 | SCLC | OriginalPaper

    SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

    Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by …

  8. Open Access 05-09-2023 | SCLC | OriginalPaper

    Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)

    Small cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by an exceptionally high proliferative rate, early metastasis and poor prognosis with an expected median overall survival < 12 months. At the time of diagnosis …

  9. 01-05-2022 | Lung Cancer | OriginalPaper

    A Comparative Analysis of White Matter Structural Networks on SCLC Patients After Chemotherapy

    Previous sMRI, DTI and rs-fMRI studies in small cell lung cancer (SCLC) patients have reported that patients after chemotherapy had gray and white matter structural alterations along with functional deficits. Nonetheless, few are known regarding …

  10. Open Access 09-08-2023 | SCLC | Erratum

    Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

  11. Open Access 24-06-2023 | SCLC | ReviewPaper

    Emerging therapies targeting DLL3 in SCLC

    Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis.

  12. Open Access 01-11-2021 | SCLC | ReviewPaper

    Durvalumab: A Review in Extensive-Stage SCLC

    Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with …

  13. 01-05-2022 | Adenovirus | OriginalPaper

    In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide

    Cancer is a leading global cause of death in the twenty-first century, and its incidence is rapidly rising. Lung cancer has the highest incidence and mortality rate, accounting for 11.6% and 18.4%, respectively (Sung et al. 2020 ). From the …

  14. Open Access 01-12-2022 | Lung Cancer | OriginalPaper

    A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol

    Lung cancer is the leading cause of cancer-related deaths worldwide [ 1 ]. Small-cell lung cancer (SCLC) accounts for 12–15% of lung cancers. The age-adjusted incidence rate of SCLC in the U.S. was reported to be approximately 6 per 100,000 in 2016 …

  15. 05-07-2022 | Lung Cancer | OriginalPaper

    Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study

    Patients with extensive-stage small-cell lung cancer (ES-SCLC) have high relapse rates and poor prognosis. Anlotinib monotherapy has shown promising efficacy for patients with ES-SCLC and has a non-overlapping toxicity profile with chemotherapy.

  16. Open Access 01-12-2023 | Lung Cancer | OriginalPaper

    MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat

    Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, characterized by a short doubling time, high growth fraction, and early development of widespread metastases [ 1 ]. Around two thirds of patients present with extensive stage (ES) …

  17. Open Access 01-11-2021 | Lung Cancer | ReviewPaper

    Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion

    Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) …

  18. 01-10-2020 | SCLC | ReviewPaper

    Atezolizumab: A Review in Extensive-Stage SCLC

    Atezolizumab (Tecentriq®), a fully humanized, monoclonal anti-programmed cell death ligand-1 (PD-L1) antibody, is the first immune checkpoint inhibitor to be approved, in combination with carboplatin and etoposide, for the treatment of adult …

  19. 01-02-2021 | Lung Cancer | OriginalPaper

    Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)

    Small cell lung cancer (SCLC) accounts for 13–17% of all lung cancer cases diagnosed, of which 70% of SCLC patients are in an advanced stage when initially diagnosed, and the 5-year survival rate of SCLC patients is only 7% (Paz-Ares et al. 2019 ; …

  20. 01-08-2020 | SCLC | Letter

    A rare case of Opsoclonus-Myoclonus associated with SCLC

    We report a case of a patient with a newly diagnosed small-cell lung cancer (SCLC), with paraneoplastic Opsoclonus-Myoclonus Syndrome (p-OMS) as the presenting symptom. Patients with OMS may have very debilitating symptoms, despite an albeit …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.